Archives: Projects/Publication

OCT-L

 

 Designação do Projeto / Project Title

Registo de Direitos de Propriedade Industrial do OCT-L

International Patent Application of OCT-L

 

Código do Projeto / Project nº | 35637

 

Objetivo Principal/ Main Purpose | Apresentar um pedido de patente internacional e proteção internacional da propriedade industrial da tecnologia OCT-Leakage.

Present an international patent application and international protection of the industrial property of the OCT-Leakage

 

Região de Intervenção / Region of Intervention| Região Centro / Centre Region of Portugal

 

Entidade Beneficiária / Beneficiary Entity | AIBILI – Associação para Investigação Biomédica e Inovação em Luz e Imagem

 

Data de Aprovação / Approval date | 23-10-2017

Data de Inicio / Beginning date |01-10-2017

Data de conclusão / Conclusion date | 30-09-2021

Custo Total Elegível / Total eligible Cost | 35.120,00€

Financiamento / Funding | 29.852,00€

 

Apoio Financeiro publico nacional / National public financial support | Sistema de Apoio à Investigação Científica e Tecnológica – Proteção de Direitos da Propriedade Intelectual

 

Atividades e resultados atingidos / Activities and results |

As patentes para esta tecnologia foram atribuídas a nível Europeu em Agosto de 2020 e nos Estados Unidos da América em Fevereiro de 2022.

The patents for this technology were granted in August 2020 by the European Patent Office and by the USPTO.gov in the United States in February 2022.

 

CHAD

 

 

  • ‣ START-Portugal-Register: The PorTuguese Survey on anTicoagulated pAtients RegisTer

 

  • ‣ ESSENCE – The Effectiveness, Safety and Patient Experience on Oncology Treatments: Achieving Real-World Evidence

 

  • ‣ Rede DruSER.Net – Drug Safety and Effectiveness Network

 

 

CEC

teste

 

Investigator Initiated Studies

 

Diabetic Retinopathy

  1. CORDIS – Characterization of retinal vascular disease in eyes with mild to moderate Nonproliferative diabetic retinopathy in Diabetes type 2, using novel non-invasive imaging methods, in a longitudinal and prospective clinical study with 2 years of duration

ClinicalTrials.gov nº: NCT03696810

Financial support: Portugal 2020 – 02/SAICT/2017 – Project nº 030375

 

  1. RECOGNISED – Retinal and Cognitive Dysfunction in Type 2 Diabetes: Unraveling the Common Pathways and Identification of Patients at Risk of Dementia

ClinicalTrials.gov nº: NCT04281186

Financial support: European Union – H2020-SC1-BHC-01-2019-847749

 

  1. PROGRESS 10 – Progression of Diabetic Retinopathy. Identification of Signs and Surrogate outcomes -10-year follow-up

ClinicalTrials.gov nº: NCT04650165

 

  1. CHART – Characterization of Retinal disease progression in eyes with NPDR in diabetes Type 2 using non-invasive procedures

ClinicalTrials.gov nº: NCT04636307

Financial support: IIR Grant from Bayer

 

  1. RICHARD – Retinal Ischemia characterization in diabetes

ClinicalTrials.gov nº: NCT05112445

Financial support: IIR Grant from Boehringer Ingelheim

 

  1. Exploratory project – Diabetic Retinopathy: from clinical to cellular phenotyping

Financial support: AIBILI

 

  1. PREDICTION – Prediction of Retinal Ischemia in Diabetes

ClinicalTrials.gov nº: NCT05581225

 

Age-Related Macular Degeneration

  1. MACUSTAR – Intermediate AMD: Development of novel clinical endpoints for clinical trials in patients with a regulatory and patient access intention

ClinicalTrials.gov nº: NCT03349801

Financial Support: European Union and EFPIA – Innovative Medicines Initiative 2 Joint Undertaking – Grant Agreement nº 116076

 

  1. AMDMetab – Metabolomics: An Integrative Tool for Investigating the Pathogenesis of Age-related Macular Degeneration

Partner: Massachusetts Eye and Ear Infirmary (MEEI) and the Harvard Medical School, Boston, USA

ClinicalTrials.gov nº: NCT04241536

Financial Support: EURETINA Clinical Research Award

 

Retinal Degenerative Diseases

  1. STAR – Development of a Model for Advanced Screening for Timely Treatment of Age-Related Eye Diseases

 

  1. EYEMARKER – Characterization of potential biomarkers of Eye Disease and Vision Loss

ClinicalTrials.gov nº: NCT02500862

 

Industry Sponsored Clinical Trials

 

Diabetic Macular Edema

    1. A two-year, three-arm, randomized, double-masked, multicentre, phase III study assessing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to diabetic macular edema (KESTREL)

    EudraCT nº: 2017-004742-23

     

    1. A Multicenter, Open-Label Extension Study To Evaluate The Long-Term Safety And Tolerability Of Faricimab In Patients With Diabetic Macular Edema (Rhone-X)

    EudraCT nº: 2020-000402-29

     

    1. A Phase 2 Randomized, Placebo-controlled, Double-masked Proof-of-concept Study to Investigate the Efficacy and Safety of Runcaciguat (BAY 1101042) in Patients With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NEON)

    EudraCT nº: 2020-002333-15

     

    Age-Related Macular Degeneration

     

    1. A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular age-related macular degeneration (Mylight)

    EudraCT nº: 2019-004838-41

     

    Glaucoma

     

    1. Long-Term Surveillance Study of Latanoprost to Monitor Hyperpigmentation changes in the eye in Pediatric Populations (A6111144)

     

    Neurological Disorders

     

    1. A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis (EXPAND)

    EudraCT nº: 2012-003056-36

     

    1. Multicenter, non-comparative extension to study AC-058B301, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with relapsing multiple sclerosis (OPTIMUM)

    EudraCT nº: 2016-004719-10

     

    Oncology

     

    1. A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: the PROOF Trial (PROOF)

    EudraCT nº: 2018-004004-19

Apetrechamento da AIBILI para reforço de áreas de intervenção através da aquisição de equipamentos de natureza técnica e tecnológica

 

 

 

 

Designação do Projeto:

Apetrechamento da AIBILI para reforço de áreas de intervenção através da aquisição de equipamentos de natureza técnica e tecnológica

 

Código do projeto: CENTRO-01-0246-FEDER-000023

 

Objetivo principal: A AIBILI definiu um plano de ação estratégico para os próximos três anos que inclui reforçar-se como centro de referência a nível europeu: 1) na coordenação e apoio logístico na realização de investigação clínica e translacional; 2) em inovação e desenvolvimento de biomarcadores de imagem da progressão de doenças da retina; 3) na avaliação da viabilidade económica e do processo translacional de tecnologias de saúde.

 

Região da Intervenção: Região Centro

Entidade Beneficiária: AIBILI

Data de aprovação: 16/04/2020

Data de início: 22/05/2019

Data de conclusão: 21/05/2021

Custo total elegível: 483.754,00€

Financiamento: FEDER 314.440,10€

 

Objetivos, atividades e resultados esperados:

Este plano de ação tem como objetivos:

  • Estender e optimizar a capacidade de afirmação a nível internacional através do reforço da capacitação e da qualidade da infraestrutura tecnológica (investimentos em recursos humanos e equipamento)
  • Estimular relações institucionais entre empresas e unidades de investigação, fortalecendo sistemas regionais de inovação e desenvolvimento de competências
  • Promover o investimento no desenvolvimento de produtos e serviços inovadores
  • Promover a valorização e a transferência de tecnologia dando origem a novos produtos/aplicações
  • Promover a participação em redes e plataformas internacionais de investigação e inovação que criam as condições para intercâmbios e projetos colaborativos multinacionais
  • Fortalecer a posição como infraestrutura dotando-a de capacidade efetiva de resposta especializada aos desafios do tecido económico produtivo.

 

Intensive safety monitoring program of antineoplastic medicines: a pilot study in a Portuguese oncology hospital

Intensive safety monitoring program of antineoplastic medicines: a pilot study in a Portuguese oncology hospital

Intensive safety monitoring program of antineoplastic medicines: a pilot study in a Portuguese oncology hospital

Mendes D, Rigueiro G, Silva R, Penedones A, Alves C, Sousa G, Batel Marques F

Journal of Oncology Pharmacy Practice

2019

Increased High-Density Lipoprotein Levels Associated with Age-Related Macular Degeneration: Evidence from the EYE-RISK and European Eye Epidemiology Consortia

Increased High-Density Lipoprotein Levels Associated with Age-Related Macular Degeneration: Evidence from the EYE-RISK and European Eye Epidemiology Consortia

Increased High-Density Lipoprotein Levels Associated with Age-Related Macular Degeneration: Evidence from the EYE-RISK and European Eye Epidemiology Consortia

Colijn JM, den Hollander AI, Demirkan A, Cougnard-Grégoire A, Verzijden T, Kersten E, Meester-Smoor MA, Merle BMJ, Papageorgiou G, Ahmad S, Mulder MT, Costa MA, Benlian P, Bertelsen G, Bron AM, Claes B, Creuzot-Garcher C, Erke MG, Fauser S, Foster PJ, Hammond CJ, Hense HW, Hoyng CB, Khawaja AP, Korobelnik JF, Piermarocchi S, Segato T, Silva R, Souied EH, Williams KM, van Duijn CM, Delcourt C, Klaver CCW; European Eye Epidemiology Consortium and EYE-RISK Consortium

Ophthalmology. 2018 Oct 10. pii: S0161-6420(18)31091-1

2018